Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Changes in Behaviour Symptoms of Patients with Attention Deficit/Hyperactivity Disorder during Treatment: Observation from Different Informants.

Wang LJ, Chen CK, Huang YS.

Psychiatry Investig. 2013 Mar;10(1):1-7. doi: 10.4306/pi.2013.10.1.1. Epub 2013 Jan 25.

3.
4.

A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.

5.

Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.

Ercan ES, Akyol Ardic U, Kabukcu Basay B, Ercan E, Basay O.

Atten Defic Hyperact Disord. 2013 Dec;5(4):377-85. doi: 10.1007/s12402-013-0111-0. Epub 2013 Jun 5.

PMID:
23737214
6.

Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.

Wang LJ, Chen CK, Huang YS.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):246-53. doi: 10.1089/cap.2014.0015. Epub 2015 Jan 9.

PMID:
25574708
7.

Normative data and psychometric properties of the child behavior checklist and teacher rating form in an Iranian community sample.

Tehrani-Doost M, Shahrivar Z, Pakbaz B, Rezaie A, Ahmadi F.

Iran J Pediatr. 2011 Sep;21(3):331-42.

8.

Symptoms defined by parents' and teachers' ratings in attention-deficit hyperactivity disorder: changes with age.

Oncü B, Oner O, Oner P, Erol N, Aysev A, Canat S.

Can J Psychiatry. 2004 Jul;49(7):487-91.

PMID:
15362254
10.

Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.

Biederman J, Pliszka SR.

J Pediatr. 2008 Mar;152(3):394-9. doi: 10.1016/j.jpeds.2007.07.052. Epub 2007 Oct 24.

PMID:
18280848
11.

[Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children].

Escobar R, Hervas A, Soutullo C, Mardomingo MJ, Uruñuela A, Gilaberte I.

Actas Esp Psiquiatr. 2008 Sep-Oct;36(5):285-94. Spanish.

PMID:
18830848
12.

Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate-OROS (OROS-MPH): A Multi-center, Open-label Study in Korea.

Kim BN, Kim YN, Cheong US, Kim JW, Hwang JW, Shin MS, Cho SC; Korean OROS-MPH Study Group..

Clin Psychopharmacol Neurosci. 2011 Apr;9(1):29-35. doi: 10.9758/cpn.2011.9.1.29. Epub 2011 Apr 30.

13.

Association of the GRIN2B rs2284411 polymorphism with methylphenidate response in attention-deficit/hyperactivity disorder.

Kim JI, Kim JW, Park JE, Park S, Hong SB, Han DH, Cheong JH, Choi JW, Lee S, Kim BN.

J Psychopharmacol. 2016 Sep 13. pii: 0269881116667707. [Epub ahead of print]

PMID:
27624150
14.

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C.

Cochrane Database Syst Rev. 2015 Nov 25;(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Review.

15.
16.

An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.

Shang CY, Pan YL, Lin HY, Huang LW, Gau SS.

J Child Adolesc Psychopharmacol. 2015 Sep;25(7):566-73. doi: 10.1089/cap.2015.0035. Epub 2015 Jul 29.

PMID:
26222447
17.
18.

Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study.

Ercan ES, Uysal T, Ercan E, Akyol Ardic U.

Pharmacopsychiatry. 2012 Jan;45(1):13-9. doi: 10.1055/s-0031-1286348. Epub 2011 Oct 12. Erratum in: Pharmacopsychiatry. 2015 Jul;48(4-5):183. Ardıc, U A [corrected to Akyol Ardic, U].

PMID:
21993869
19.
20.

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.

Ginsberg L, Katic A, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Adler LA.

Curr Med Res Opin. 2011 Jun;27(6):1097-107. doi: 10.1185/03007995.2011.567256. Epub 2011 Mar 28.

PMID:
21438796

Supplemental Content

Support Center